↓ Skip to main content

Oncotarget

Article Metrics

HDAC inhibitors enhance the immunotherapy response of melanoma cells

Overview of attention for article published in Oncotarget, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
7 news outlets
twitter
10 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
78 Dimensions

Readers on

mendeley
101 Mendeley
Title
HDAC inhibitors enhance the immunotherapy response of melanoma cells
Published in
Oncotarget, May 2017
DOI 10.18632/oncotarget.17950
Pubmed ID
Authors

Laurence Booth, Jane L. Roberts, Andrew Poklepovic, John Kirkwood, Paul Dent

Abstract

We focused on the ability of the pan-histone deacetylase (HDAC) inhibitors AR42 and sodium valproate to alter the immunogenicity of melanoma cells. Treatment of melanoma cells with HDAC inhibitors rapidly reduced the expression of multiple HDAC proteins as well as the levels of PD-L1, PD-L2 and ODC, and increased expression of MHCA. In a cell-specific fashion, melanoma isolates released the immunogenic protein HMGB1 into the extracellular environment. Very similar data were obtained in ovarian and H&NSCC PDX isolates, and in established tumor cell lines from the lung and kidney. Knock down of HDAC1, HDAC3, HDAC8 and HDAC10, but not HDAC6, recapitulated the effects of the HDAC inhibitors on the immunotherapy biomarkers. Using B16 mouse melanoma cells we discovered that pre-treatment with AR42 or sodium valproate enhanced the anti-tumor efficacy of an anti-PD-1 antibody and of an anti-CTLA4 antibody. In the B16 model, both AR42 and sodium valproate enhanced the anti-tumor efficacy of the multi-kinase inhibitor pazopanib. In plasma from animals exposed to [HDAC inhibitor + anti-PD-1], but not [HDAC inhibitor + anti-CTLA4], the levels of CCL2, CCL5, CXCL9 and CXCL2 were increased. The cytokine data from HDAC inhibitor plus anti-PD-1 exposed tumors correlated with increased activated T cell, M1 macrophage, neutrophil and NK cell infiltration. Collectively, our data support the use of pan-HDAC inhibitors in combination with kinase inhibitors or with checkpoint inhibitor antibodies as novel melanoma therapeutic strategies.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 101 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 19%
Researcher 14 14%
Student > Master 11 11%
Student > Bachelor 10 10%
Student > Doctoral Student 9 9%
Other 16 16%
Unknown 22 22%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 31 31%
Medicine and Dentistry 19 19%
Pharmacology, Toxicology and Pharmaceutical Science 9 9%
Agricultural and Biological Sciences 5 5%
Immunology and Microbiology 5 5%
Other 7 7%
Unknown 25 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 58. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2021.
All research outputs
#570,703
of 21,552,983 outputs
Outputs from Oncotarget
#176
of 14,120 outputs
Outputs of similar age
#13,305
of 289,921 outputs
Outputs of similar age from Oncotarget
#12
of 1,005 outputs
Altmetric has tracked 21,552,983 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 14,120 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,921 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 1,005 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.